Dennis Byrski

Dr. Dennis Byrski

Ehemaliger wissenschaftlicher Mitarbeiter

Innovation and Entrepreneurship Research



Arbeitsbereiche:

Innovationsökonomik, Wissenschaftsökonomik, empirische Industrieökonomik, Gesundheitsökonomik

Wissenschaftlicher Werdegang

10/2016 - 10/2021
Wissenschaftlicher Mitarbeiter und Doktorand am Max-Planck-Institut für Innovation und Wettbewerb (Innovation and Entrepreneurship Research) und an der Munich Graduate School of Economics, LMU München
Titel der Dissertation: “From Scientific Research to Healthcare Markets – Empirical Essays on the Economics of Pharmaceutical Innovation”

09/2019 - 12/2019
Gastwissenschaftler am Laboratory for Innovation Science at Harvard (LISH), Harvard Business School

10/2013 - 02/2016
Studium der Volkswirtschaftslehre (M.Sc.), Universität zu Köln
sowie Tsinghua University (Peking, China)

10/2012 - 09/2013
Studium der Volkswirtschaftslehre (B.Sc.), Heinrich-Heine-Universität Düsseldorf

10/2009 - 09/2012
Studium der Betriebswirtschaftslehre (B.Sc.), Heinrich-Heine-Universität Düsseldorf
sowie Grenoble Graduate School of Business (Grenoble, Frankreich)

Beruflicher Werdegang

07/2016 - 09/2016
Praktikant, Frontier Economics, Köln

04/2016 - 06/2016
Praktikant, Bundeskartellamt (Grundsatzabteilung Ökonometrie), Bonn

02/2016 - 04/2016
Praktikant, Accenture Strategy, Berlin

03/2015 - 02/2016
Studentischer Mitarbeiter, Institut der Deutschen Wirtschaft (IW) im
Kompetenzfeld Tarifpolitik und Arbeitsbeziehungen, Köln

02/2013 - 08/2014
Studentischer Mitarbeiter, Verlagsgruppe Handelsblatt, Düsseldorf

04/2012 - 07/2012 und 04/2011 - 07/2011
Tutor und studentische Hilfskraft am Lehrstuhl für betriebswirtschaftliche Steuerlehre
der Heinrich-Heine-Universität, Düsseldorf

02/2012 - 04/2012
Praktikant, KPMG AG, Düsseldorf

Stipendien

Seit 05/2018
Science Production Function Society Fellow am Laboratory for Innovation Science at Harvard (LISH), Harvard Business School

2012 - 2016
Stipendium der Friedrich-Naumann-Stiftung für die Freiheit,
Begabtenförderung aus Mitteln des Bundesministeriums für Bildung und Forschung (BMBF)

2009 - 2011
NRW-Stipendium "Chancen Nutzen", Begabtenförderung aus Mitteln des Ministeriums für Innovation, Wissenschaft und Forschung des Landes NRW

Publikationen

Artikel in referierten Fachzeitschriften

Baruffaldi, Stefano Horst; Byrski, Dennis; Gaessler, Fabian (2020). Fire and Mice: The Effect of Supply Shocks on Basic Science, Academy of Management Proceedings, 2020 (1). DOI

  • We study how a negative supply shock to research-related assets affects the production of scientific knowledge. In particular, we exploit the 1989 Morrell Park fire that destroyed a considerable share of the world's largest mice breeding facility, the Jackson Laboratory, and killed approximately 400,000 mice. This fire led to an unforeseen and substantial supply shortage in mice for the North American biomedical research community, which we can isolate at the strain and scientist level based on proprietary archival data. Using difference-in-differences estimations, we find that the scientific productivity of affected scientists decreases when measured in simple publication counts, but much less so when we adjust for the publications' quality. Moreover, affected researchers are more likely to initiate research that is unrelated to their previous work. This indicates that affected scientists switched research trajectories but maintained their scientific impact. In the aggregate, the temporary supply shortage of particular mice strains led to a permanent decrease in their usage among U.S.\ scientists. These results highlight the important role of supply chains in basic science."

Batista, Pedro Henrique D.; Byrski, Dennis; Lamping, Matthias; Romandini, Roberto (2019). IP-Based Incentives Against Antimicrobial Crisis: A European Perspective, IIC - international review of intellectual property and competition law, 50 (1), 30-76. DOI

  • The field of antimicrobials is considered to be facing a crisis. Increasing
    microbial resistance is creating a demand for new drugs, which however is not being
    matched by privately funded R&D. The reasons for this market failure are of a
    technical and economic nature. The present article analyzes what changes to IP-
    based incentives are conceivable in the European Union (EU) in order to address the
    antimicrobial crisis. Since the assessment of the suitability of the analyzed options
    depends on interdisciplinary research, this article also proposes a research agenda to
    be considered for the implementation of public policies in this field.

Herausgeberwerke

Romandini, Roberto; Kur, Annette; Walz, Axel; Valtere, Laura; Slowinski, Peter R.; Wright, Gordon; Gaessler, Fabian; Batista, Pedro Henrique D.; Byrski, Dennis; Fischer, Marius; Rivas, Victoria (2018). Study on the legal aspects of Supplementary Protection Certificates in the EU. Final report. Brussel: European Commission. DOI

    Beiträge in Sammelwerken

    Gaessler, Fabian; Byrski, Dennis (2018). Section 16.2 - Duration of the SPC (Art. 13 Reg. 469/2009) - Effective length of SPC protection, in: Roberto Romandini, Reto M. Hilty, Annette Kur (Hg.), Study on the Legal Aspects of Supplementary Protection Certificates in the EU - Final Report, 378-379. Brussels: European Commission.

      Slowinski, Peter R.; Romandini, Roberto; Gaessler, Fabian; Byrski, Dennis (2018). Chapter 16 - Duration of the SPC (Art. 13 Reg. 469/2009), in: Roberto Romandini, Reto M. Hilty, Annette Kur (Hg.), Study on the Legal Aspects of Supplementary Protection Certificates in the EU - Final Report, 377-385. Brussels: European Commission.

        Byrski, Dennis; Gaessler, Fabian (2018). Annex V - SPC Statistics to Chapter 7, in: Roberto Romandini, Reto M. Hilty, Annette Kur (Hg.), Study on the Legal Aspects of Supplementary Protection Certificates in the EU - Final Report, 1-16. Brussels: European Commission.

          Romandini, Roberto; Gaessler, Fabian; Byrski, Dennis (2018). Chapter 7 - Overall Use of the SPC System in the EU, in: Roberto Romandini, Reto M. Hilty, Annette Kur (Hg.), Study on the Legal Aspects of Supplementary Protection Certificates in the EU - Final Report, 91-105. Brussels: European Commission.

            Monographien

            Byrski, Dennis (2021). From Scientific Research to Healthcare Markets: Empirical Essays on the Economics of Pharmaceutical Innovation. DOI

            • This dissertation offers new insights into the determinants of biomedical science and pharmaceutical innovation, each in a self-contained chapter. The first chapter investigates the functioning of research tool markets, which are important input factors into science. Specifically, it observes why short-term distortions to supply have enduring effects on tool adoption and, thus, the direction of scientific research. The second chapter examines whether pharmaceutical companies adjust their follow-on innovation activities when patentability standards increase. To this end, it analyses changes in the innovation incentives caused by a drug’s marketing authorization. The third chapter explores the relationship between downstream shifts in demand and upstream research. It studies whether a policy-induced increase in market size affects scientific publishing by universities and corporations. In summary, evidence from these micro-economic analyses may contribute to designing effective and efficient public policies that help stimulate R&D activities, foster the development of new pharmaceutical treatments, and eventually improve public health.

            Lesch, Hagen; Byrski, Dennis (2016). Flächentarifvertrag und Tarifpartnerschaft in Deutschland: Ein historischer Rückblick (IW-Analysen, 107). Köln: Institut der Deutschen Wirtschaft Köln Medien GmbH.

              Diskussionspapiere

              Byrski, Dennis; Wang, Lucy Xiaolu (2024). Marketing Authorization and Strategic Patenting: Evidence from Pharmaceuticals. DOI

              • Patents are designed to incentivize innovation, but pharmaceutical firms often extend market exclusivity with secondary patents on marginally beneficial improvements. Such behaviors evoke discussions about raising patentability standards. This study examines whether pharmaceutical firms move away from filing strategic patents once the focal drug gains marketing authorization and the disclosed trial-related information becomes novelty-threatening prior art. We construct novel patent-drug dyadic data and leverage unique European drug patent and marketing contexts. Using an event study methodology, we exploit plausibly exogenous variation in the length of time from patent filing to drug approval. First, we illustrate that drugs with early and late marketing authorization share similar ex ante patent and drug characteristics. Second, we support the hypothesis that strategic patenting behavior decreases substantially after marketing authorization. In contrast, meaningful follow-on innovations remain unaffected. Third, we show that these effects are likely driven by obstacles in the enforceability of marginal patents filed after approval. We analyze heterogeneity across firm type, patent type, disease type, and enforceability. Our results suggest that post-marketing increases in patentability standards are welfare-enhancing with examiner scrutiny and firm self-adjustment. We highlight the importance of better data provision to patent examiners to increase the quality of follow-up inventions.

              Byrski, Dennis; Gaessler, Fabian; Higgins, Matthew John (2021). Market Size and Research: Evidence from the Pharmaceutical Industry, Max Planck Institute for Innovation & Competition Research Paper, No. 21-16.

              • Prior literature has established a link between changes in market size and pharmaceutical innovation; whether a link exists with scientific research remains an open question. If upstream research is not responsive to these changes, the kinds of scientific discoveries that flow into future drug development could be disconnected from downstream demand. We explore this question by exploiting the effects of quasi-experimental variation in market size introduced by Medicare Part D. We find no causal relationship between market size and biomedical research in the decade following the implementation of Medicare Part D. While many factors have been shown to motivate scientists to conduct research, this result suggests that changes in market size provide no such incentive. We do find, however, limited support for a response by corporate scientists conducting applied research. Implications for pharmaceutical innovation policy are discussed.
              • Also published as NBER Working Paper No. 28858

              Vorträge

              18.10.2021
              Market Size and Research: Evidence from the Pharmaceutical Industry
              DRUID Conference
              Ort: Kopenhagen, Dänemark


              10.09.2021
              Market Size and Research: Evidence from the Pharmaceutical Industry
              EPIP Conference
              Ort: Madrid, Spanien


              01.07.2021
              Market Size and Research: Evidence from the Pharmaceutical Industry
              BEWIP Seminar, TU München
              Ort: München


              21.12.2020
              Fire and Mice: The Effect of Supply Shocks on Basic Science
              Innovation Brown Bag Seminar, LMU
              Ort: online


              30.09.2020
              Patents, Products, and Cumulative Innovation: Evidence From the Pharmaceutical Industry
              Verein für Socialpolitik Jahrestagung, Universität zu Köln
              Ort: online


              10.09.2020
              Market Size and Scientific Research: Evidence From Medicare Part D
              Forschungsseminar
              Ort: online


              03.08.2020
              Fire and Mice: The Effect of Supply Shocks on Basic Science
              EPFL Virtual Innovation Seminar, École polytechnique fédérale de Lausanne
              Ort: online


              10.07.2020
              Fire and Mice: The Effect of Supply Shocks on Basic Science
              Workshop Organization, Economics and Policy of Scientific Research (WOEPSR), Max-Planck-Institut für Innovation und Wettbewerb
              Ort: online


              11.05.2020
              Market Size and Scientific Research: Evidence From Medicare Part D
              Innovation Brown Bag Seminar, LMU
              Ort: online


              06.03.2020
              Patents, Products, and Cumulative Innovation: Evidence From the Pharmaceutical Industry
              Mannheim Centre for Competition and Innovation (MaCCI), Annual Conference at the ZEW Mannheim
              Ort: online


              03.03.2020
              Patents, Products, and Cumulative Innovation: Evidence From the Pharmaceutical Industry
              Forschungsseminar
              Ort: Zugspitze


              22.01.2020
              Fire and Mice: The Effect of Supply Shocks on Basic Science
              TIME Seminar
              Ort: München


              16.12.2019
              Fire and Mice: The Effect of Supply Shocks on Basic Science
              2nd Research on Innovation, Science and Entrepreneurship Workshop (RISE2), Max-Planck-Institut für Innovation und Wettbewerb
              Ort: München


              11.12.2019
              Drug Approval and Cumulative Innovation: Evidence From the Pharmaceutical Industry
              Research Seminar at the Laboratory for Innovation Science at Harvard/Harvard University
              Ort: Cambridge, Massachusetts, USA


              14.11.2019
              Drug Approval and Cumulative Innovation: Evidence From the Pharmaceutical Industry
              Ph.D. Seminar at the David Eccles School of Business/University of Utah
              Ort: Salt Lake City, Utah, USA


              04.11.2019
              Fire and Mice: The Effect of Supply Shocks on Basic Science
              Department Meeting at the Laboratory for Innovation Science at Harvard/Harvard University
              Ort: Cambridge, Massachusetts, USA


              13.09.2019
              Patent Terms, Marketing Authorization and Cumulative Innovation: Evidence From the Pharmaceutical Industry
              European Policy for Intellectual Property (EPIP)
              Ort: Zürich, Schweiz


              05.09.2019
              Patent Terms, Marketing Authorization and Cumulative Innovation: Evidence From the Pharmaceutical Industry
              Doktorandenseminar, Max-Planck-Institut für Innovation und Wettbewerb
              Ort: Tutzing


              24.06.2019
              Fire and Mice: The Effect of Supply Shocks on Basic Science
              Ludwig-Maximilians-Universität München
              Ort: München


              05.03.2019
              Fire and Mice: The Effect of Supply Shocks on Basic Science
              Doktorandenseminar, Max-Planck-Institut für Innovation und Wettbewerb
              Ort: Zugspitze

              Projekte